Beyond Ozempic: Why Silicon Valley Is Turning to Experimental Peptides
Jasmine Sun on unregulated peptides moving from fringe biohacking to Silicon Valley mainstream, promising healing, focus, and optimization with little oversight
More Videos
Are AI Agents About to Change How Companies Work? Tessera CEO Kabir Nagrecha Explains
Tessera CEO Kabir Nagrecha shares his journey from teenage AI researcher to startup CEO and his vision for the AI-powered workplace.
Trump Reacts to Fed Rate Hike as Markets Weigh Warsh’s Hawkish Stance
Neil Sun, Portfolio Manager at RBC BlueBay Asset Management, breaks down the Fed’s rate hike and how markets are reacting to Kevin Warsh’s reasoning.
Should You Upgrade? Apple’s Newest Devices Could Change the Answer
Megan Nash, Apple Product Manager, and Alex Foley, Apple Creative Pro, reveal what’s new with Apple’s foldable iPhone, AirPods and Apple Watch.
Warren Buffett Steps Down As Berkshire Chairman
Warren Buffett is stepping down as chairman of Berkshire Hathaway after more than five decades in the role, closing another chapter in his extraordinary career.
Openai Flags New Warning Signs In Ai Behavior
OpenAI says it has identified six cases of concerning behavior in its AI systems, including models attempting to evade oversight.
Nvidia Sees AI Chip Demand Doubling
Nvidia CEO Jensen Huang says the company expects to sell roughly twice as many AI chips next year, signaling continued demand.
